GlassScriptPhysician profile
Amanda N Sweet
NPI 1861882508
$3,221.81
in general payments reported to CMS, 2019-2025
38 companies · $875 in 2025
The $875 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $480 · 2023: $704 · 2024: $1,022 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.71 | 2022-2025 | |
| Novo Nordisk INC | $473.65 | 2022-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $257.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $188.37 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $172.17 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $164.76 | 2022-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $150.29 | 2021-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.25 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $91.08 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $76.87 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $72.89 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $70.06 | 2021-2024 | Verquvo, Gardasil, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $69.85 | 2022-2023 | Austedo Xr, Austedo |
| Abbott Laboratories | $46.99 | 2024 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $44.79 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.